Note 4 Investors

According to me market having low risk, because of results of bluechip companys all are positive, which indicate the indian market strength, On Friday we saw a high jump because of BHARTI AIRTEL and IDEA and many companies supported to NIFTY and SENSEX., may be Sensex will be touch the figure of 18000+ to 19000+ and Nifty touch the figure of 5350+ to 5450+, So the risk side is almost minimize. 

BEST OF LUCK FOR YOUR INVESTMENTS.  

--
Rohit Saxena
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

Equity tips 4 u.

Bharti Airtel Ltd

	Bharti Airtel net profit rises 39.28% in the March 2008 quarter Friday, April 25, 2008
	Net profit of Bharti Airtel rose 39.28% to Rs 1792.30 crore in the quarter ended March 2008 as against Rs 1286.84 crore during the previous quarter ended March 2007. Sales rose 42.06% to Rs 7413.73 crore in the quarter ended March 2008 as against Rs 5218.73 crore during the previous quarter ended March 2007. For the full year, net profit rose 54.82% to Rs 6244.20 crore in the yearended March 2008 as against Rs 4033.22 crore during the previous year ended March 2007. Sales rose 44.45% to Rs 25703.51 crore in the year ended March 2008 as against Rs 17794.43 crore during the previous year ended March 2007.

                     ( Buy BHARTI AIRTEL NEXT TARGET IS 980+)

 

Idea Cellular Ltd

	Idea Cellular net profit rises 110.74% in the March 2008 quarter Thursday, April 24, 2008
	Net profit of Idea Cellular rose 110.74% to Rs 278.20 crore in the quarter ended March 2008 as against Rs 132.01 crore during the previous quarter ended March 2007. Sales rose 138.12% to Rs 1972.40 crore in the quarter ended March 2008 as against Rs 828.31 crore during the previous quarter ended March 2007. For the full year, net profit rose 108.02% to Rs 1044.39 crore in the year ended March 2008 as against Rs 502.06 crore during the previous year ended March 2007. Sales rose 53.90% to Rs 6719.99 crore in the year ended March 2008 as against Rs 4366.40 crore during the previous year ended March 2007. ( BUY IDEA CELLULAR TARGET PRICE 122+)

                BUY RNRL TARGET PRICE 136+

                BUY RPL TARGET PRICE 205+

                BUY CAIRN INDIA LTD TARGET PRICE 270+

                BUY ESSAR OIL TARGET PRICE 305+

                BUY SUZLON ENERGY TARGET PRICE 324+

                BUY JPASSOCIATE TARGET PRICE 270+

                BUY UNITECH TARGET PRICE 307+

                BUY DLF TARGET PRICE 715+

                BUY CIPLA TARGET PRICE 255+

                BUY NOIDA TOLL TAREGT PRICE 56+

               
--
Rohit Saxena
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

equity tips 4 u.

 

BANK OF INDIA target price 330+

Bank Of India has informed the Exchange that "Our Bank will publish theAudited Results for the financial Year 2007-08 within three months fromthe end of Financial Year i.e. before June 30, 2008."

 

BUY Suzlon target price 324+

 

Buy JPassociate (b/w 211 to 218) target price 235+

 

BUY GMR TARGET PRICE 174+

 

--
Rohit Saxena
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

equity tips 4u

buy Suzlon Energy (buy b/w 282 to 295) target price 324+
--
Rohit Saxena
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

equitytips 4 u

buy cairn india ltd (b/w 222 to 237) target price 251

--
Rohit Saxena
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

news on Bhel

Bharat Heavy Electricals Ltd

	Bhel inches ahead Monday, April 07, 2008
	Meanwhile, the BSE Sensex was up 75.55 points, or 0.49%, to 15,418.67 as a worse-than-expected US payrolls data on Friday, 4 April 2008, which showed a fall of 80,000 jobs in March 2008, raised expectations of further interest rate cut by the US Federal Reserve. On BSE, 8,047 shares were traded in the counter. The scrip had an average daily volume of 1.98 lakh shares in the past one quarter. The stock hit a high of Rs 1660 and a low of Rs 1620 so far during the day. The stock had a 52-week high of Rs 2925 on 7 November 2007 and a 52-week low of Rs 1167.50 on 5 April 2007. Public sector power equipment major Bharat Heavy Electricals (Bhel) had underperformed the market over the past one month till 4 April 2008, declining 21.49% compared to the Sensex's fall of 7.25%. It had also underperformed the market in the past one quarter, declining 35.81% compared to Sensex's decline of 25.83%. The company's current equity is Rs 489.52 crore. Face value per share is Rs 10. The current price of Rs 1645 discounts its Q3 December 2007 annualized EPS of Rs 63.07, by a PE multiple of 26.08. On 3 April 2008, Bhel's reported provisional turnover of Rs 21,608 crore, a 15.31% growth and provisional net profit of Rs 2,815 crore, a 16.56% growth in the financial year 2007-08 over 2006-07. The 16.56% growth in Bhel's net profit in the year ended March 2008 over the year ended March 2007 as per the provisional results, was muted in the backdrop of a 38% growth in net profit achieved in the nine months ended December 2007 over nine months ended December 2006, raising concerns that the Q4 March 2008 results would be bad. Types of insurance policies On 17 March 2008, Bhel secured orders worth around Rs 2,030 crore for an upcoming 1,000-megawatt thermal power project. On 29 February 2008, the company received an order worth Rs 1893 crore from GSPC Pipavav Power Co in western India for a 700 megawatt plant. On 14 February 2008, Bhel bagged an order worth Rs 200 crore from Oil & Natural Gas Corporation for supplying oil field equipment. On 8 February 2007, the company bagged an order worth Rs 3390 crore for setting up two units of 500 megawatt each in a thermal power station in northern Uttar Pradesh. Bhel's net profit rose 15.6% to Rs 771.90 crore on 14.4% growth in net sales to Rs 4964.14 crore in Q3 December 2007 over Q3 December 2006. Bhel is engaged in manufacturing and distributing electrical, electronic, and mechanical and nuclear power equipment.

 

 

--
Rohit Saxena
Kotak Securities
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

news on suzlon Energy

Suzlon Energy Ltd

	Additional order energies Suzlon Energy Wednesday, April 02, 2008
	Meanwhile, the BSE Sensex was up 325.72 points, or 2.09%, to 15,953.67 on positive cues from global markets. US stocks rallied on Tuesday, 1 April 2008, after Lehman Brothers said it raised $4 billion in an offering of convertible preferred shares, which soothed fears it was heading for a fate similar to that of Bear Stearns. On BSE, 28.51 lakh shares were traded in the counter. The scrip had an average daily volume of 13.24 lakh shares in the past one quarter. The stock hit a high of Rs 296 and a low of Rs 283.35 so far during the day. The stock had a 52-week high of Rs 460 on 9 January 2008 and a 52-week low of Rs 186.40 on 3 April 2007. The large-cap scrip had outperformed the market over the past one month till 31 March 2008, declining 6.29% compared to the Sensex's fall of 11%. It had however underperformed the market in the past one quarter, declining 32.43% compared to Sensex's decline of 22.94%. The company's current equity is Rs 299.38 crore. Face value per share is Rs 2. The current price of Rs 290.10 discounts its Q3 December 2007 annualized EPS of Rs 9.04, by a PE multiple of 32.09. The original contract was for delivery of 400 mega watt (MW) of turbine capacity in 2008 and 2009, and now has been expanded to include an additional 200 MW in 2009. Suzlon Energy's net profit rose 91.9% to Rs 338.18 crore on 49.7% growth in net sales to Rs 1654.96 crore in Q3 December 2007 over Q3 December 2006. Suzlon Energy provides customers with total wind power solutions.

--
Rohit Saxena
phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

news on Ranbaxy

Ranbaxy Laboratories Ltd

	Ranbaxy Laboratories launches worlds first Bio-generic recombinant injectible for the treatment of O Thursday, April 03, 2008
	Ranbaxy Laboratories has announced the launch of BONISTA- Teriparatide injection (recombinant human parathyroid hormone) for the treatment of Osteoporosis, in collaboration with Virchow Biotech, Hyderabad, India. Ranbaxy is the first company to launch this bio generic product in the world.    The product has been indigenously researched at Virchow Biotech and developed with and from the Department of Science and Technology, Government of India.    Virchow Biotech, part of the Hyderabad based Rs 600 crore Virchow Group, engages in research, development, manufacture and marketing of a wide range of unique classical biologicals and high value recombinant bio-generie products for serious life-threatening diseases at affordable prices. Established in 2001, Virchow Biotech produces over 15 biological products in state of the art production facilities equipped to manufacture topical biologicals, recombinants and parenteral biopharmaceuticals. The facilities have been audited and certified by various regulatory agencies for their conformance to current Good Manufacturing Practices (cGMPs). Virchow Biotcch also monitors and conducts large multi-centric clinical trials and is a Government of India recognized R&D Centre.    The company made this announcement during the trading hours today, 03 April 2008.

 

 

--
Rohit Saxena
Kotak Securities
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com

my Recommandation

be Careful for tommrow's market, might be risky and you will see more fluctutaion n volatile market.

--
Rohit Saxena
Kotak Securities
Phone No: 09891265905
Mail Id: rohit_9sep@indiatimes.com